Ekmekçi A, Sayli A
Department of Medical Biology and Genetics, Faculty of Medicine, Gazi University, Ankara, Turkey.
Mutat Res. 1995 Apr;334(2):175-83. doi: 10.1016/0165-1161(95)90009-8.
Cytogenetic analyses were carried out in lymphocytes of 15 untreated tuberculosis (tb) patients and 15 other tb patients who had received combined tuberculostatic chemotherapy HRZ (isoniazid+rifampicin+pyrazinamide) for 2 months. The frequency of chromosomal aberrations and sister-chromatid exchanges (SCEs) did not show any statistically significant differences in the patients before treatment and after exposure to combined HRZ therapy as compared to controls (p > 0.05). However, we observed that the mitotic index was significantly decreased in both groups (p < 0.05). Based on the results of the present study, we believe there is no indication for a chromosome damaging effect of HRZ and their metabolites in human lymphocytes in vivo after treatment of tuberculosis patients with optimum doses.
对15名未经治疗的结核病患者和15名接受联合抗结核化疗HRZ（异烟肼+利福平+吡嗪酰胺）2个月的其他结核病患者的淋巴细胞进行了细胞遗传学分析。与对照组相比，治疗前和接受联合HRZ治疗后的患者中，染色体畸变和姐妹染色单体交换（SCE）的频率没有显示出任何统计学上的显著差异（p>0.05）。然而，我们观察到两组的有丝分裂指数均显著降低（p<0.05）。基于本研究的结果，我们认为在用最佳剂量治疗结核病患者后，HRZ及其代谢产物在体内对人淋巴细胞没有染色体损伤作用的迹象。
